Eslicarbazepine acetate 1200 mg

DRUG2 trials

Sponsors

Sumitomo Pharma America, Inc., Bial - Portela C S.A.

Conditions

BIPOLAR I DISORDEREpilepsy

Phase 2

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

TerminatedNCT01824602

Bial - Portela C S.A.BIPOLAR I DISORDER

Start: 2006-02-28End: 2006-11-30Updated: 2014-03-27

Phase 3

Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic

CompletedNCT01091662

Sumitomo Pharma America, Inc.Epilepsy

Start: 2010-06-30End: 2012-11-30Updated: 2016-10-24

Related Papers

Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.

2015-03-2843 citations